Invitrogen has introduced the FreeStyle Max system - designed for large scale protein production in the preferred cell lines for a number of bio-pharmaceutical and pre-clinical applications
Invitrogen's FreeStyle Max system enables wide range of bio-pharmaceutical and pre-clinical applications.
"Our first try with the new system gave over ten-fold higher yields of the same recombinant protein from the same vectors," said David Wilson, vice-president, therapeutic antibody development at Evogenix, one of the early evaluators of the FreeStyle Max system.
The FreeStyle Max System is a protein production technology developed for rapid, large-scale generation of post-translationally modified, functional proteins in Chinese hamster ovary (CHO) and HEK-293 suspension cell cultures.
It is the first commercially available large-scale transient transfection system optimized with CHO suspension culture - the preferred cell line for pre-clinical testing and producing FDA-approved protein for therapeutic applications.
Using suspension cultures and transient transfection methods, researchers are now able to generate significantly higher levels of protein in the preferred cell lines for these applications in days compared to months required for generating stable cell lines.
"We listened to our customers and matched our product development focus to their requirements for protein production in their applications," concluded Mark Gardner, Invitrogen's vice president of molecular biology essentials.
"With the introduction of FreeStyle Max, we have delivered a new system of technologies to meet these needs."
